Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$32.51 USD
-4.22 (-11.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $32.50 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
APLS 32.51 -4.22(-11.49%)
Will APLS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLS
Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q2 Earnings: A Look at Key Metrics
Other News for APLS
Apellis selloff brings 'very attractive entry point,' says Citi
Maintaining Buy Rating on Apellis Pharmaceuticals Amid European Setback and US Market Focus
Apellis Pharmaceuticals Hold Rating Justified Amidst EU Setbacks and Market Challenges
First Week of APLS November 15th Options Trading
Apellis Pharmaceuticals declines afters CHMP's third negative opinion on Syfovre